UY26787A1 - 3-AZABICICLO DERIVATIVES (3.1.0.) HEXANO USEFUL IN THERAPY - Google Patents

3-AZABICICLO DERIVATIVES (3.1.0.) HEXANO USEFUL IN THERAPY

Info

Publication number
UY26787A1
UY26787A1 UY26787A UY26787A UY26787A1 UY 26787 A1 UY26787 A1 UY 26787A1 UY 26787 A UY26787 A UY 26787A UY 26787 A UY26787 A UY 26787A UY 26787 A1 UY26787 A1 UY 26787A1
Authority
UY
Uruguay
Prior art keywords
useful
derivatives
azabiciclo
hexano
therapy
Prior art date
Application number
UY26787A
Other languages
Spanish (es)
Inventor
Ashley Edward Fenwick
Bernard Joseph Banks
Douglas James Critcher
David Morris Gethin
Stephen Paul Gibson
Mr Graham Lunn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY26787A1 publication Critical patent/UY26787A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de la fórmula I, en la que los sustituyentes son como se definieron en la presente, y los derivados o profármacos farmacéutica o veterinariamente aceptables de éstos son farmaceútica y veterinariamente útiles, en particular, se unen a receptores opiáceos (por ejemplo receptores opiáceos mu, kappa y delta ). Es probable que sean útiles en el tratamiento de enfermedades o afecciones moduladas por receptores opiáceos, por ejemplo síndrome del intestino irritable, estrenimiento, náuseas, vómitos, prurito, trastornos alimentarios, sobredosis opiáceas, depresión, adicción al tabaco y al alcohol, disfunción sexual, shock, apoplejía, dano espinal y trauma cerebral.Compounds of the formula I, in which the substituents are as defined herein, and the pharmaceutically or veterinarily acceptable derivatives or prodrugs thereof are pharmaceutically and veterinarily useful, in particular, bind to opioid receptors (eg mu opiate receptors , kappa and delta). They are likely to be useful in the treatment of diseases or conditions modulated by opioid receptors, for example irritable bowel syndrome, constipation, nausea, vomiting, pruritus, eating disorders, opioid overdose, depression, tobacco and alcohol addiction, sexual dysfunction, shock, stroke, spinal damage and brain trauma.

UY26787A 2000-06-23 2001-06-21 3-AZABICICLO DERIVATIVES (3.1.0.) HEXANO USEFUL IN THERAPY UY26787A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015562.2A GB0015562D0 (en) 2000-06-23 2000-06-23 Heterocycles
PCT/IB2001/001035 WO2001098267A1 (en) 2000-06-23 2001-06-07 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity

Publications (1)

Publication Number Publication Date
UY26787A1 true UY26787A1 (en) 2002-01-31

Family

ID=9894368

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26787A UY26787A1 (en) 2000-06-23 2001-06-21 3-AZABICICLO DERIVATIVES (3.1.0.) HEXANO USEFUL IN THERAPY

Country Status (34)

Country Link
EP (1) EP1292574A1 (en)
JP (1) JP2004512263A (en)
KR (1) KR20040002386A (en)
CN (1) CN1639121A (en)
AP (1) AP2002002698A0 (en)
AR (1) AR028969A1 (en)
AU (1) AU781837B2 (en)
BG (1) BG107329A (en)
BR (1) BR0111867A (en)
CA (1) CA2412188A1 (en)
CZ (1) CZ20023967A3 (en)
DO (1) DOP2001000187A (en)
DZ (1) DZ3368A1 (en)
EA (1) EA005117B1 (en)
GB (1) GB0015562D0 (en)
HR (1) HRP20020998A2 (en)
HU (1) HUP0301228A3 (en)
IL (1) IL153427A0 (en)
IS (1) IS6637A (en)
MA (1) MA26915A1 (en)
MX (1) MXPA02012878A (en)
NO (1) NO20026168L (en)
NZ (1) NZ523141A (en)
OA (1) OA12293A (en)
PA (1) PA8519401A1 (en)
PE (1) PE20020253A1 (en)
PL (1) PL365956A1 (en)
SK (1) SK17172002A3 (en)
TN (1) TNSN01094A1 (en)
UA (1) UA73176C2 (en)
UY (1) UY26787A1 (en)
WO (1) WO2001098267A1 (en)
YU (1) YU91802A (en)
ZA (1) ZA200210278B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL368919A1 (en) 2001-10-22 2005-04-04 Pfizer Products Inc. 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
JP2005531557A (en) * 2002-05-17 2005-10-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Use of effective compounds as selective opiate receptor modulators
DE10259245A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivatives of asimadolin with covalently bound acids
EP2070922B1 (en) 2004-02-23 2011-08-17 Glaxo Group Limited Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
WO2006133945A1 (en) * 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
WO2007113258A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
EP2636407A3 (en) 2007-03-30 2013-11-06 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
TWI423801B (en) * 2007-08-27 2014-01-21 Theravance Inc 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
CA2936749C (en) 2010-06-11 2019-07-09 Joshua R. Giguere Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
EP2621902B1 (en) 2010-09-28 2017-04-12 Panacea Biotec Ltd 3-azabicyclo[3.1.0]hexane compounds useful for the treatment of cns disorders
CN105764888B (en) * 2013-11-20 2018-04-06 株式会社三和化学研究所 A kind of new 3 azabicyclos [3.1.0] hexame derivatives and its medical usage
CN113307760A (en) 2015-05-20 2021-08-27 宇部兴产株式会社 Novel crystal of salt of 3-azabicyclo [3.1.0] hexane derivative and medical application thereof
EP3582779B1 (en) * 2017-02-17 2024-04-17 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
BR112019016775A2 (en) 2017-02-17 2020-03-31 Trevena, Inc. DELTA-OPIOIDE MODULATING RECEIVER COMPOUNDS CONTAINING 7-MEMBER AZA-HETEROCYCLIC, METHODS OF USE AND PRODUCTION OF THE SAME
JPWO2018159716A1 (en) 2017-03-02 2019-12-26 株式会社三和化学研究所 Drugs for alcohol use disorders
CN108250088B (en) * 2018-01-04 2020-10-30 四川之江高新材料股份有限公司 Preparation method of N, N, N '-trimethyl-N' -hydroxyethyl bisaminoethylether

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065230A (en) * 1959-03-16 1962-11-20 Burroughs Wellcome Co Azabicyclohexanes and method of preparing them
IL86061A (en) * 1987-04-16 1992-07-15 Lilly Co Eli Derivatives of trans-3,4-isomer of 4-methyl-4-phenyl-piperidines,process for their preparation and pharmaceutical compositions containing them
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
DE4341403A1 (en) * 1993-12-04 1995-06-08 Basf Ag N-substituted 3-azabicycloalkane derivatives, their preparation and use
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
PE20001420A1 (en) * 1998-12-23 2000-12-18 Pfizer CCR5 MODULATORS

Also Published As

Publication number Publication date
HRP20020998A2 (en) 2004-02-29
IL153427A0 (en) 2003-07-06
BG107329A (en) 2003-07-31
YU91802A (en) 2006-05-25
NO20026168D0 (en) 2002-12-20
HUP0301228A3 (en) 2005-08-29
AU6259101A (en) 2002-01-02
HUP0301228A2 (en) 2003-08-28
JP2004512263A (en) 2004-04-22
CA2412188A1 (en) 2001-12-27
ZA200210278B (en) 2003-12-19
GB0015562D0 (en) 2000-08-16
AR028969A1 (en) 2003-05-28
DOP2001000187A (en) 2002-03-30
MA26915A1 (en) 2004-12-20
DZ3368A1 (en) 2001-12-27
AP2002002698A0 (en) 2002-12-31
NO20026168L (en) 2003-02-18
CZ20023967A3 (en) 2004-02-18
BR0111867A (en) 2003-07-01
MXPA02012878A (en) 2003-05-14
KR20040002386A (en) 2004-01-07
UA73176C2 (en) 2005-06-15
EA200201269A1 (en) 2003-06-26
PE20020253A1 (en) 2002-04-08
WO2001098267A8 (en) 2003-02-27
OA12293A (en) 2004-03-18
PL365956A1 (en) 2005-01-24
NZ523141A (en) 2005-06-24
PA8519401A1 (en) 2002-12-30
CN1639121A (en) 2005-07-13
EA005117B1 (en) 2004-10-28
TNSN01094A1 (en) 2005-11-10
SK17172002A3 (en) 2004-09-08
AU781837B2 (en) 2005-06-16
EP1292574A1 (en) 2003-03-19
IS6637A (en) 2002-11-28
WO2001098267A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
UY26787A1 (en) 3-AZABICICLO DERIVATIVES (3.1.0.) HEXANO USEFUL IN THERAPY
MXPA04004370A (en) Polycyclic guanine derivative phosphodiesterase v inhibitors.
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
GB0329214D0 (en) Novel compounds
BR0316753A (en) Treatment method for sexual dysfunction
ECSP056202A (en) DERIVATIVES OF IMIDAZOL AS ANTAGONISTS OF THE GLUTAMATE RECEIVER
CA2422698A1 (en) Indoline derivatives and their use as 5-ht2 receptor ligands
WO2006018279A3 (en) Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament
CR9149A (en) RAPAMYCIN DERIVATIVES AND USES OF THE SAME IN THE TREATMENT OF NEUROLOGICAL DISORDERS
MX2007004794A (en) Thienopyridines as allosteric potentiators of the m4 muscarinic receptor.
PT1736157E (en) Morphinan derivatives as anti-itching agent
CR9622A (en) DERIVATIVES OF PIRAZOLO [3,4-D] AZEPIN AS HISTAMINE ANTAGONISTS H3
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
TN2012000259A1 (en) Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl} carbamate and its purification for use thereof as pharmaceutical substance
TW200514781A (en) Novel compounds
PA8527901A1 (en) DERIVATIVES OF QUINAZOLIN AS AN ANTAGONIST OF ADRENÈRGICO ALFA-1
BR0308567A (en) apomorphine glycoside and orthoester glycoside derivatives, analogs, and their uses
TW200621223A (en) Acyclic 1,3-diamines and uses therefor
PA8592801A1 (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
SV2002000459A (en) DERIVATIVES OF SULFONAMIDS REF. X-13840
GB0317491D0 (en) Organic compounds
AR043306A1 (en) N- UREIDOALQUIL-PIPERIDINAS AS MODULATORS OF THE ACTIVITY OF THE CHEMIOKIN RECEPTOR
DOP2004000920A (en) IMIDAZOL DERIVATIVES AS GLUTAMATE RECEIVER ANTAGONISTS
TH84856B (en) How to relieve pain
TH84856A (en) How to relieve pain

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140212